News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
748,211 Results
Type
Article (44213)
Company Profile (467)
Press Release (703514)
Multimedia
Podcasts (144)
Webinars (23)
Section
Business (209526)
Career Advice (2048)
Deals (36221)
Drug Delivery (139)
Drug Development (84143)
Employer Resources (174)
FDA (16805)
Job Trends (15228)
News (354684)
Policy (33306)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2687)
Accelerated approval (52)
Adcomms (31)
Allergies (176)
Alliances (51115)
ALS (222)
Alzheimer's disease (1865)
Antibody-drug conjugate (ADC) (493)
Approvals (17177)
Artificial intelligence (710)
Autoimmune disease (310)
Automation (56)
Bankruptcy (374)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (228)
Biotechnology (325)
Bladder cancer (203)
Brain cancer (76)
Breast cancer (779)
Cancer (6056)
Cardiovascular disease (498)
Career advice (1742)
Career pathing (45)
CAR-T (347)
CDC (58)
Celiac Disease (3)
Cell therapy (954)
Cervical cancer (47)
Clinical research (72848)
Collaboration (2187)
Company closure (5)
Compensation (1439)
Complete response letters (91)
COVID-19 (2807)
CRISPR (117)
C-suite (1188)
Cystic fibrosis (161)
Data (8149)
Decentralized trials (3)
Denatured (46)
Depression (174)
Dermatology (91)
Diabetes (595)
Diagnostics (7006)
Digital health (56)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (345)
Drug pricing (213)
Drug shortages (32)
Duchenne muscular dystrophy (305)
Earnings (93449)
Editorial (70)
Employer branding (21)
Employer resources (153)
Events (123510)
Executive appointments (1122)
FDA (20624)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1814)
Gene editing (255)
Generative AI (58)
Gene therapy (787)
GLP-1 (1109)
Government (4836)
Grass and pollen (6)
Guidances (409)
Healthcare (19356)
HIV (83)
Huntington's disease (58)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (101)
Immunology and inflammation (321)
Immuno-oncology (101)
Indications (197)
Infectious disease (3157)
Inflammatory bowel disease (229)
Inflation Reduction Act (17)
Influenza (139)
Intellectual property (298)
Interviews (319)
IPO (16957)
IRA (53)
Job creations (3718)
Job search strategy (1443)
JPM (67)
Kidney cancer (19)
Labor market (102)
Layoffs (599)
Leadership (42)
Legal (8032)
Liver cancer (102)
Longevity (33)
Lung cancer (797)
Lymphoma (438)
Machine learning (61)
Management (59)
Manufacturing (1083)
MASH (199)
Medical device (14097)
Medtech (14226)
Mergers & acquisitions (20522)
Metabolic disorders (1576)
mRNA (238)
Multiple sclerosis (194)
NASH (20)
Neurodegenerative disease (451)
Neuropsychiatric disorders (114)
Neuroscience (3461)
Neurotech (1)
NextGen: Class of 2026 (6772)
Non-profit (4605)
Now hiring (78)
Obesity (751)
Opinion (313)
Ovarian cancer (230)
Pain (266)
Pancreatic cancer (317)
Parkinson's disease (383)
Partnered (34)
Patents (606)
Patient recruitment (697)
Peanut (63)
People (61098)
Pharmaceutical (79)
Pharmacy benefit managers (33)
Phase 1 (22907)
Phase 2 (32156)
Phase 3 (23729)
Pipeline (9041)
Policy (336)
Postmarket research (2607)
Preclinical (9841)
Press Release (67)
Prostate cancer (318)
Psychedelics (64)
Radiopharmaceuticals (349)
Rare diseases (1160)
Real estate (6083)
Recruiting (71)
Regulatory (26005)
Reports (56)
Research institute (2513)
Resumes & cover letters (355)
Rett syndrome (39)
RNA editing (27)
RSV (88)
Schizophrenia (186)
Series A (307)
Series B (227)
Service/supplier (11)
Sickle cell disease (121)
Special edition (29)
Spinal muscular atrophy (171)
Sponsored (49)
Startups (3835)
State (2)
Stomach cancer (19)
Supply chain (130)
Tariffs (88)
The Weekly (95)
Vaccines (1132)
Venture capital (119)
Weight loss (489)
Women's health (132)
Worklife (21)
Date
Today (42)
Last 7 days (680)
Last 30 days (3356)
Last 365 days (30936)
2026 (13461)
2025 (31062)
2024 (36285)
2023 (41011)
2022 (52276)
2021 (56760)
2020 (54918)
2019 (47415)
2018 (35693)
2017 (33022)
2016 (32345)
2015 (38397)
2014 (32186)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (759)
Alabama (99)
Alaska (7)
Arizona (360)
Arkansas (16)
Asia (41210)
Australia (6867)
California (13659)
Canada (3829)
China (1416)
Colorado (583)
Connecticut (600)
Delaware (416)
Europe (90721)
Florida (2022)
Georgia (436)
Hawaii (3)
Idaho (62)
Illinois (1085)
India (91)
Indiana (610)
Iowa (25)
Japan (551)
Kansas (135)
Kentucky (52)
Louisiana (43)
Maine (76)
Maryland (1627)
Massachusetts (9862)
Michigan (370)
Minnesota (741)
Mississippi (6)
Missouri (147)
Montana (35)
Nebraska (29)
Nevada (143)
New Hampshire (89)
New Jersey (3591)
New Mexico (32)
New York (3543)
North Carolina (1787)
North Dakota (10)
Northern California (6841)
Ohio (404)
Oklahoma (23)
Oregon (44)
Pennsylvania (2723)
Puerto Rico (29)
Rhode Island (51)
South America (1126)
South Carolina (86)
South Dakota (2)
Southern California (5369)
Tennessee (215)
Texas (2166)
United States (48268)
Utah (404)
Vermont (1)
Virginia (331)
Washington D.C. (81)
Washington State (1112)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
748,211 Results for "antibe therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Antibe Announces TSX Delisting Review
Antibe Therapeutics Inc. announced that the Toronto Stock Exchange is reviewing the eligibility for continued listing on the TSX of the securities of the Company.
April 16, 2024
·
2 min read
Press Releases
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
April 30, 2026
·
10 min read
Press Releases
enGene Announces Name Change to enGene Therapeutics Inc.
April 7, 2026
·
8 min read
Press Releases
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
May 20, 2026
·
4 min read
Press Releases
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
May 14, 2026
·
6 min read
Policy
Antibe Provides Update on CCAA Proceedings
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“ Stay ”) under the Companies’ Creditors Arrangement Act (the “ CCAA ”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “ Court ”) on April 18, 2024.
April 19, 2024
·
2 min read
Press Releases
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
May 5, 2026
·
8 min read
Press Releases
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
April 23, 2026
·
6 min read
Press Releases
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
May 12, 2026
·
6 min read
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. is extending the Early Warrant Exercise Incentive Program for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.
February 1, 2024
·
3 min read
1 of 74,822
Next
